Market Overview

UPDATE: Citigroup Raises Eli Lilly PT to $60 on Eli Lilly on Potential Upside

Share:
Related LLY
SunTrust's Latest Comments On Merck
Morgan Stanley's Major Pharma Q1 Preview
Bristol-Myers to Transfer Certain Erbitux Rights to Eli Lilly - Analyst Blog (Zacks)

Citigroup maintained Eli Lilly and Company (NYSE: LLY) with a Buy rating and raised the price target from $55.00 to $60.00.

Citigroup noted, "Lilly's base business is performing ahead of our expectations (Alimta, Elanco, Diabetes and Emerging markets). Consequently, we continue to see upside for Lilly due to the asymmetric risk reward given the minimal value being discounted for the key pipeline agent ramucirumab (cancer). Buy-rated Pfizer, Lilly and Forest remain our favoured names in US pharma."

Eli Lilly closed at $54.32 on Tuesday.

Latest Ratings for LLY

DateFirmActionFromTo
Mar 2015SunTrust Robinson HumphreyMaintainsBuy
Mar 2015Leerink SwannMaintainsOutperform
Feb 2015JefferiesMaintainsBuy

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

Around the Web, We're Loving...